Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

The fuel gauge showed just a tiny amount of hydrogen in the vehicle’s tank, and someone on the sales staff at Roseville ...

Researchers have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder ...

In a real-world study, researchers found this data by comparing treatment patterns, healthcare resource utilization, and ...

Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR ...

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...

A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free ...

Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...

Scientists have supercharged CAR-T therapy, making it more powerful against elusive cancer cells that usually escape ...

A person with neuroblastoma, which occurs when developing nerve cells in children turn cancerous, has remained tumour-free for over 18 years thanks to CAR T-cell therapy ...

Autolus Therapeutics' main focus is on obe-cel, a CAR T-cell therapy for B-cell ALL, with a strong likelihood of approval.